Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

broxuridine

A halogenated thymidine analogue with potential antineoplastic and radiosensitizing activities. Bromodeoxyuridine competes with thymidine for incorporation into DNA, resulting in DNA mutation and the inhibition of cell proliferation. As a radiosensitizer, this agent is associated with the inhibition of repair of radiation-induced DNA double-strand breaks.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	5-bromodeoxyuridine bromo deoxyuridine bromodeoxyuridine bromouracil deoxyriboside bromouridine
US brand name:	Broxine Neomark Neomark-BU
Abbreviation:	5-BrdU BrdU
Chemical structure:	5-bromo-2'-deoxyuridine 5-bromouracil deoxyriboside 5-bromouracil-2-deoxyriboside

broxuridine

Search NCI's Drug Dictionary